NINIVAGGI DANIEL A 4
4 · Indivior Pharmaceuticals, Inc. · Filed Jan 28, 2026
Research Summary
AI-generated summary of this filing
Indivior (INDV) Director Daniel Ninivaggi Receives 3,722 RSUs
What Happened
Daniel A. Ninivaggi, a director of Indivior Pharmaceuticals, was granted 3,722 restricted stock units (RSUs) on January 26, 2026. The Form 4 reports the acquisition price as $0.00 and total reported value $0 (award/grant code A). This is a compensation award, not an open‑market purchase or sale.
Key Details
- Transaction date: 2026-01-26; filing date: 2026-01-28 (Form 4 accession 0001257599-26-000006) — filing appears timely.
- Shares/units granted: 3,722 RSUs; reported price: $0.00; reported aggregate value: $0.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnote: RSUs represent a contingent right to one share each and vest on the day immediately preceding the issuer’s first annual meeting after the grant, subject to continued service.
Context
RSUs are a form of equity compensation that convert to actual shares only if and when they vest; they do not require the insider to pay cash at grant and do not indicate an immediate purchase or sale. Director awards are common as part of routine compensation and should be interpreted differently than open‑market purchases (which can signal a direct personal investment).
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-26+3,722→ 20,645 total
Footnotes (1)
- [F1]Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.